Henning Sievert

Dr. Henning Sievert


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
Karel KostevKarel Kostev
Karel Kostev
HSHenning Sievert
Henning Sievert
MKMarcel Konrad
Marcel Konrad
CTChristian Tanislav
Christian Tanislav
JBJens Bohlken
Jens Bohlken
Background: The IQVIA Disease Analyzer (DA) database is a major outpatient electronic health record dataset in Germany. Over recent years, it has been increasingly used to study neurological diseases, comorbidities, treatment patterns, and long-term sequelae. We narratively summarized neurology-related studies using the German IQVIA Disease Analyzer (DA) database published since 2020 and to highlight methodological considerations relevant for interpreting DA-based neurological research. Methods: We conducted a narrative review of DA-based studies published between January 2020 and December 2025. PubMed was searched using DA-related keywords and major neurological disease terms. Eligible articles included peer-reviewed cohort, case–control, or descriptive studies using DA outpatient data. Results: The review identified studies covering epilepsy, cerebrovascular outcomes, Parkinson’s disease, dementia, multiple sclerosis, migraine, and sensory disorders. Most used retrospective cohort or nested case–control designs with regression or propensity score methods. Follow-up durations ranged from 3 to 10 years. Results consistently reflected routine care outpatient diagnostic and prescribing patterns. Discussion: Strengths of DA studies include large patient populations, long follow-up, and detailed prescription information. Limitations include reliance on outpatient ICD-10 coding, lack of detailed neurological phenotyping, and potential residual confounding and bias. Conclusions: DA-based analyses generate clinically relevant routine care evidence on neurological conditions in the German outpatient setting. Proper methodological safeguards and complementary data sources are required to contextualize findings for clinical and epidemiological use.

Verified
Journal Article
Open access
PDF file
Karel KostevKarel Kostev
Karel Kostev
BLBeate Leppert
Beate Leppert
MPMaximilian Lukas Peters
Maximilian Lukas Peters
HSHenning Sievert
Henning Sievert
MKMarcel Konrad
Marcel Konrad
MLMark Luedde
Mark Luedde
Background: Primary non-adherence (PNA)—failure to dispense a newly prescribed medication—is an early barrier to effective treatment. This study aimed to estimate PNA to oral anticoagulants in patients with atrial fibrillation (AF) in Germany and to identify associated factors. Methods: In this retrospective cohort study, first prescriptions of vitamin K antagonists (VKAs), direct thrombin inhibitors, or direct factor Xa inhibitors issued to AF patients between 2016 and 2025 in the IQVIA Disease Analyzer database were combined with pharmacy dispensing records in the Longitudinal Prescription (LRx) database. First prescriptions preceded by a dispensing of the same class within 365 days were excluded. PNA was defined as failure to dispense within 30 days; associated factors were assessed using logistic regression with generalized estimating equations. Results: The study included 57,290 first prescriptions in 53,815 patients (mean age 75.5 years; 49.7% women). PNA occurred in 10.6% (VKAs 14.4%, direct thrombin inhibitors 11.7%, direct factor Xa inhibitors 10.1%). Direct factor Xa inhibitors (odds ratio [OR] 0.67; 95% confidence interval [CI] 0.62–0.72), prior myocardial infarction (OR 0.79), and dementia (OR 0.85) were associated with lower odds of PNA, whereas ischemic heart disease (OR 1.18) and hypertension (OR 1.11) were associated with higher odds. Non-dispensing of the first prescription was strongly associated with non-dispensing of subsequent prescriptions. Conclusions: Approximately one in ten first oral anticoagulant prescriptions in AF was not dispensed within 30 days, most frequently for VKAs.

29 May 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
Karel KostevKarel Kostev
Karel Kostev
MPMaximilian Lukas Peters
Maximilian Lukas Peters
HSHenning Sievert
Henning Sievert
MKMatthias Kalder
Matthias Kalder
Background: Aromatase inhibitors (AIs) are widely used in hormone receptor-positive breast cancer but may adversely affect bone health. Evidence on their independent association with fracture risk compared with tamoxifen (TAM) remains inconsistent. Methods: In this retrospective cohort study, women with an initial prescription of TAM or AIs between 2016 and 2024 were identified in the IQVIA Longitudinal Prescription (LRx) database. Their prescription histories were combined with records from the IQVIA Disease Analyzer (DA) database using a validated co-therapy-based approach. Patients were then followed for up to five years. Kaplan–Meier analyses estimated cumulative fracture incidence, and Cox regression models assessed associations in unadjusted, age-adjusted, and fully adjusted analyses. Results: The study included 8938 TAM users and 14,594 AI users. Five-year cumulative incidence of all fractures was higher in the AI group than in the TAM group (14.8% vs. 9.2%). In fully adjusted primary analyses, AI therapy was not significantly associated with overall fracture risk (HR 1.10, 95% CI 0.99–1.23). A modest association persisted for major osteoporotic fractures (HR 1.24, 95% CI 1.05–1.46). Secondary exploratory analyses (age-stratified and fracture-type-specific models) showed patterns consistent with the primary results but were not powered or corrected for confirmatory inference. Conclusions: Aromatase inhibitor therapy was associated with a higher fracture incidence than tamoxifen, but much of this difference was explained by age and comorbidities. Both treatment-related effects and underlying patient characteristics contribute to fracture risk, underscoring the importance of individualized bone health assessment and targeted preventive strategies in women receiving endocrine therapy.